Clin Assoc Prof Ng Chau Hsien Matthew

Dr Matthew Ng is the Head of GI Oncology at the National Cancer Centre Singapore and co-chairs the GI cancers service line delivery within the SingHealth Academic Medical Health Cluster. He obtained his PhD from the Institute of Cancer Research (London, UK) and research interests are in developing novel treatments for GI cancers particularly peritoneal directed therapies for upper GI cancers and as well as Early phase cancer drug development. He is the oncology lead for Upper GI cancers at SingHealth and is part of the Singapore Gastric Cancer Consortium, Singapore Peritoneal Oncology Study Group and Singapore Translational Cancer Consortium (GI and Early Phase trials track). As the Clinical Director of the Investigational Medicine Unit (SingHealth) he oversees the conduct of inpatient early phase trials for healthy volunteers and patients from different medical specialities.  

• Graduate Diploma Healthcare Management and Leadership, Singapore Management University
• PhD (UK), Institute of Cancer Research 
• M.R.C.P (UK), Royal College of Physicians, UK 
• MBBS (London), St. Bartholomew’s and Royal London Hospital School of Medicine and Dentistry

• Co-Chair Cancer Service Line Delivery for GI cancers (SingHealth)
• Chair Named Patient Programme (NCCS)

• Brackenbury and Bourne Scholarship in Clinical Medicine, 2000 
• Heath Skynner Prize in Paediatrics, 2000 
• Draper's Prize for academic achievement 
• Proxime Accessit to the University of London Gold Medal
  

• Phase 1 Trial of OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] as Treatment in Patients with Advanced and/or Metastatic Pancreatic Adenocarcinoma 
• A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer 
• Phase I study to evaluate the safety and tolerability of ASLAN001 in combination with Oxaliplatin and Capecitabine 
• A Phase 1A/B study to evaluate the safety and tolerability of ETC-1922159 in advanced solid tumours

• Sheng T, Sundar R, Srivastava S, Ong X, Tay ST, Ma H, Uchihara T, Lian BSX, Hagihara T, Kong MS, Xu C, Ho SWT, Huang KK, Tan ALK, Ng MSW, Toh J, Ng CSY, Nasca V, Pircher CC, Randon G, Giordano S, Corso S, Lum JHY, Zhao JJ, Teh M, So JBY, Sabella G, Prabhakar S, Lee J, Ng MCH, Shitara K, Gasparello J, Fassan M, Pietrantonio F, Tan P. Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy. Gut. 2025 Oct 30:gutjnl-2024-334667. doi: 10.1136/gutjnl-2024-334667. Epub ahead of print. PMID: 41167802. [IF : 25.8]
• Masuda Y, Fong KL, Yeo D, Yeo C, Chue KM, Araba SB, Lim CW, Yeung B, Lee J, Lin J, Chia C, Ng M, Ng K, Samol J, Chia D, Teh JL, Sundar R, Yong WP, Tan HL, Muro K, Lordick F, Wainburg Z, Tan BC, Kim G, Suda K, Law S, Sano T, Gurunathan R, Chiu P, Woo E, Duong C, Yang HK, Long VD, Kim HH, Mahendren HA, Lee HJ, Samarasam I, Gotoda T, Liew R, Shabbir A, Aung MO, Terashima M, Cheong E, So J, Tan J. Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma. J Gastroenterol. 2025 Sep;60(9):1079-1090. doi: 10.1007/s00535-025-02266-4. Epub 2025 Jun 13. PMID: 40514519. [IF : 5.5]
• Park DJ, Thura M, Chiu VK, Vicuna B, Ang KH, Sanchez B, Chia PL, Kuan KY, Li J, Zhang K, Zheng WH, Hsien Ng MC, Zeng Q. The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy. Cell Rep Med. 2025 May 20;6(5):102120. doi: 10.1016/j.xcrm.2025.102120. Epub 2025 May 8. PMID: 40345181; PMCID: PMC12147911. [IF : 11.7]
• Masuda Y, Fong KL, Yeo D, Yeo C, Chue KM, Araba SB, Lim CW, Yeung B, Lee J, Lin J, Chia C, Ng M, Ng K, Samol J, Chia D, Teh JL, Sundar R, Yong WP, Tan HL, Muro K, Lordick F, Wainburg Z, Tan BC, Kim G, Suda K, Law S, Sano T, Gurunathan R, Chiu P, Woo E, Duong C, Yang HK, Long VD, Kim HH, Mahendren HA, Lee HJ, Samarasam I, Gotoda T, Liew R, Shabbir A, Aung MO, Terashima M, Cheong E, So J, Tan J. Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma. J Gastroenterol. 2025 Jun 13. doi: 10.1007/s00535-025-02266-4. Epub ahead of print. PMID: 40514519 [IF : 6.9]
• Carrie Kah-Lai Leong, Andrea Zhi Xin Foo, Ken Junyuan Goh, Anne Ann Ling Hsu, Airiel Ruth Ho, Matthew Chau Hsien Ng, Devanand Anantham, Pyng Lee. Airway interventions for tracheobronchial involvement in esophageal carcinoma: A retrospective cohort outcome study and algorithmic approach [IF : 2.9]
• Jingshan Ho, Valerie Heong , Wei Peng Yong , Ross Soo ,Cheng Ean Chee , Andrea Wong, Raghav Sundar, Yee Liang Thian, Anil Gopinatha , Mei Yan Pang, Priscillia Koe, Santhiay Jeraj, Pyar Phyu , Yar Mu , Tiffa n y Tang , Matthew Ng , David Tai, Tira Tan , Hongmei Xu , Hua Chang, Yosef Landesman , Jatin Shah , Sharon Shacham, Soo Chin Lee , Daniel S. W. Tan , Boon Cher Goh , David S. P. Tan. A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses Followed by Dose Expansion of the Selective Inhibitor of Nuclear Export (SINE) Selinexor in Asian Patients with Advanced or Metastatic Malignancies. Therapeutic Advances in Medical Oncology [IF : 6.6]
• Guanhua Zhu, Chowdhury Rafeed Rahman, Victor Getty, Probhonjon Baruah, Hanae Carrie, Avril Joy Lim, Yu Amanda Guo, Zhong Wee Poh, Ngak Leng Sim, Ahmed Abdelmoneim, Yutong Cai, Danliang Ho, Saranya Thangaraju, Polly Poon, Yi Ting Lau, Anna Gan, Sarah Ng, Denis Odinokov, Si-Lin Koo6, Dawn Q. Chong, Brenda Tay, Tira J. Tan, Yoon Sim Yap, Aik Yong Chok7, Matthew Chau Hsien Ng, Patrick Tan, Daniel Tan, Limsoon Wong, Pui Mun Wong, Iain Beehuat Tan, Anders Jacobsen Skanderup .A deep-learning model for quantifying circulating tumour DNA from the density 1 distribution of DNA-fragment lengthsNature Biomedical Engineering 2025; N.A.:N.A.-N.A. (Article; Accepted)
• Shitara K; Fleitas T; Kawakami H; Curigliano G; Narita Y; Wang F; Wardhani S O; Basade M; Rha S Y; Wan Zamaniah W I; Sacdalan D L; Ng M; Yeh K H; Sunpaweravong P; Sirachainan E; Chen M-H; Yong W P; Peneyra J L; Ibtisam M N; Lee K-W; Krishna V; Pribadi R R; Li J; Lui A; Yoshino T; Baba E; Nakayama I; Pentheroudakis G; Shoji H; Cervantes A; Ishioka C; Smyth E Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO open 2024; 9(2):102226-N.A. (Article; Published in Print)
• Kee Wanyi; Ng Kennedy Yao Yi; Liong Shun Zi; Zhou Siqin; Chee Sharon Keman; Lim Chiew Woon; Lam Justina Yick Ching; Tan Jeremy Tian Hui; Ong Hock Soo; Chan Weng Hoong; Lim Eugene Kee Wee; Lim Chin Hong; Eng Alvin Kim Hock; Lee Christabel Jing Zhi;Ng Matthew Chau HsienReal-World Outcomes for Localised Gastro-Oesophageal Adenocarcinoma Cancer Treated with Perioperative FLOT and Prophylactic GCSF Support in a Single Asian Centre. Cancers 2024; 16(21):N.A.-N.A. (Article; Published in Print) JIF: 5.2
• Zhao Joseph J; Ong Chin-Ann Johnny; Srivastava Supriya; Chia Daryl Kai Ann; Ma Haoran; Huang Kiekyon; Sheng Taotao; Ramnarayanan Kalpana; Ong Xuewen; Tay Su Ting; Hagihara Takeshi; Tan Angie Lay Keng; Teo Melissa Ching Ching; Tan Qiu Xuan; Ng Gillian; Tan Joey Wee-Shan; Ng Matthew Chau Hsien; Gwee Yong Xiang; Walsh Robert; Law Jia Hao; Shabbir Asim; Kim Guowei; Tay Yvonne; Her Zhisheng; Leoncini Giuseppe; Teh Bin Tean; Hong Jing Han; Tay Ryan Yong Kiat; Teo Chong Boon; Dings Mark P G; Bijlsma Maarten; Lum Jeffrey Huey Yew; Mathur Sachin; Pietrantonio Filippo; Blum Steven M; van Laarhoven Hanneke; Klempner Samuel J; Yong Wei Peng; So Jimmy Bok Yan; Chen Qingfeng; Tan Patrick; Sundar Raghav Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases. Gastroenterology 2024; 167(7):1384-1398.e4 (Article; Published in Print) JIF: 25.7
• Grivas Petros; Garralda Elena; Meric-Bernstam Funda; Mellinghoff Ingo K; Goyal Lipika; Harding James J; Dees E Claire; Bahleda Rastislav; Azad Nilofer S; Karippot Asha; Kurzrock Razelle; Tabernero Josep; Kononen Juha; Ng Matthew C H; Mehta Rutika; Uboha Nataliya V; Bigot Frédéric; Boni Valentina; Bowyer Samantha E; Breder Valeriy; Cervantes Andrés; Chan Nancy; Cleary James M; Dhawan Mallika; Eefsen Rikke L; Ewing James; Graham Donna M; Guren Tormod K; Won Kim Jin; Koynov Krassimir; Oh Do-Youn; Redman Rebecca; Yen Chia-Jui; Spetzler David; Roubaudi-Fraschini Marie-Claude; Nicolas-Metral Valerie; Ait-Sarkouh Rafik; Zanna Claudio; Ennaji Abdallah; Pokorska-Bocci Anna; Flaherty Keith T Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. Clinical cancer research: an official journal of the American Association for Cancer Research 2024; 30(20):4572-4583 (Article; Published in Print) JIF: 13.8
• Loh Amos Hong Pheng; Thura Min; Gupta Abhishek; Tan Sheng Hui; Kuan Kelvin Kam Yew; Ang Koon Hwee; Merchant Khurshid; Chang Kenneth Tou En; Yon Hui Yi; Chen Yong; Cheng Mathew Hern Wang; Mahadev Arjandas; Ng Matthew Chau Hsien; Seng Michaela Su-Fern; Iyer Prasad; Chia Pei Ling; Soh Shui Yen; Zeng Qi Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody. Molecular therapy oncolytics 2023; 30:153-166 (Article; Published in Print) JIF: 6.1
• Catenacci Daniel Vt; Kang Yoon-Koo; Uronis Hope E; Lee Keun-Wook; Ng Matthew Ch; Enzinger Peter C; Park Se Hoon; Gold Philip J; Lacy Jill; Hochster Howard S; Oh Sang Cheul; Kim Yeul Hong; Marrone Kristen A; Kelly Ronan J; Juergens Rosalyn A; Kim Jong Gwang; Alcindor Thierry; Sym Sun Jin; Song Eun-Kee; Chee Cheng Ean; Chao Yee; Kim Sunnie; Oh Do-Youn; Yen Jennifer; Odegaard Justin I; Lagow Errin; Li Daner; Sun Jichao; Kaminker Patrick; Moore Paul A; Rosales Minori Koshiji; Park Haeseong Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma Oncology (Williston Park, N.Y.) 2023; 37(4):176-183 (Article; Published in Print)
• Yong Wei Peng; Teo Felicia Sw; Teo Lynette Ls; Ng Matthew Ch; Tan Tira J; Low Su Ying; Wong Karmen; Ang Peter; Choo Su Pin; Lee Kim Hua; Lee Soo Chin Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody-drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. Expert opinion on drug metabolism & toxicology 2022; 18(12):805-815 (Article; Published in Print)
• Ng, Matthew; Chen, Sylvia; Ong, Whee Sze; Balachander, Akhila; Seet, Amanda; Yeong, Joe; Sutiman, Natalia; Lim, Tony Kiat Hon; Lee, Bernett; Guo, Yu Amanda; Leong, Wai Fook; Lee, Sze Sing; Lam, Justina; Choo, Su Pin; Skanderup, Anders Jacobsen; Biswas, Subhra; Tai, David; Balram, Chowbay. A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects. International Journal of Cancer. [IF : 7.4]